Frontiers in Immunology (Jan 2020)

Citrullinated Histone H3 as a Therapeutic Target for Endotoxic Shock in Mice

  • Qiufang Deng,
  • Qiufang Deng,
  • Baihong Pan,
  • Baihong Pan,
  • Hasan B. Alam,
  • Yingjian Liang,
  • Yingjian Liang,
  • Zhenyu Wu,
  • Zhenyu Wu,
  • Baoling Liu,
  • Nirit Mor-Vaknin,
  • Xiuzhen Duan,
  • Aaron M. Williams,
  • Yuzi Tian,
  • Yuzi Tian,
  • Justin Zhang,
  • Yongqing Li

DOI
https://doi.org/10.3389/fimmu.2019.02957
Journal volume & issue
Vol. 10

Abstract

Read online

Sepsis results in millions of deaths every year, with acute lung injury (ALI) being one of the leading causes of mortality in septic patients. As neutrophil extracellular traps (NETs) are abundant in sepsis, neutralizing components of NETs may be a useful strategy to improve outcomes of sepsis. Citrullinated histone H3 (CitH3) has been recently shown to be involved in the NET formation. In this study, we demonstrate that CitH3 damages human umbilical vein endothelial cells (HUVECs) and potentiates NET formation through a positive feedback mechanism. We developed a novel CitH3 monoclonal antibody to target peptidylarginine deiminase (PAD) 2 and PAD 4 generated CitH3. In a mouse model of lethal lipopolysaccharide (LPS) induced shock, neutralizing CitH3 with the newly developed anti-CitH3 monoclonal antibody attenuates inflammatory responses, ameliorates ALI, and improves survival. Our study suggests that effectively blocking circulating CitH3 might be a potential therapeutic method for the treatment of endotoxemia.

Keywords